Page 7 - வளரும் நாடுகள் மருத்துவ சோதனைகள் கூட்டு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The East African Monday December 21 2020 Summary Advertisement Uganda has enrolled its first volunteer participants in a large trial to study whether two new vaccines offer protection against HIV. The African-led PrEPVacc study will be testing two experimental combination vaccines on populations that are most at risk of getting infected with human immunodeficiency virus (HIV) to see whether the drugs provides any protection. Ugandan scientists Wednesday launched the third phase of the HIV vaccine efficacy trials in the central district of Masaka, the Ministry of Health said. The study is combining evaluation of experimental HIV vaccines and pre-exposure prophylaxis (PrEP) concurrently. PrEPVacc will test whether a new form of oral PrEP, TAF/FTC (Descovy) taken daily, is equivalent or more effective than TDF/FTC (Truvada) taken daily, in the context of the current PrEP availability situation at the five study sites in four countries: in Masaka, Uganda; Mbeya and Dar-es-Salaam,

Kwazulu natalSouth africaPontiano kaleebuCountries clinical trials partnershipMinistry of healthDeveloping countries clinical trials partnershipProf pontiano kaleebuக்வஸூல்யூ நேட்டல்நாடுகள் மருத்துவ சோதனைகள் கூட்டுஅமைச்சகம் ஆஃப் ஆரோக்கியம்வளரும் நாடுகள் மருத்துவ சோதனைகள் கூட்டு